IDH2 and acute myeloid leukemia: This is consistent with prior reports stating response is not dependent on molecular clearance, and in line with data from the ENA + AZA vs AZA alone trial for newly diagnosed older AML, where the median maximum IDH2 VAF reduction was 81.5% and occurred in responding patients with a median of 6 cycles of the combination [25].